Alkermes plc (ALKS)
- Previous Close
30.84 - Open
30.75 - Bid 26.52 x 100
- Ask 35.12 x 100
- Day's Range
30.38 - 30.95 - 52 Week Range
22.90 - 36.45 - Volume
1,047,966 - Avg. Volume
1,799,085 - Market Cap (intraday)
5.049B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
14.58 - EPS (TTM)
2.10 - Earnings Date Jul 22, 2025 - Jul 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.57
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
www.alkermes.com1,800
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ALKS
View More
Performance Overview: ALKS
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALKS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALKS
View MoreValuation Measures
Market Cap
5.09B
Enterprise Value
4.28B
Trailing P/E
14.69
Forward P/E
18.35
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.43
Price/Book (mrq)
3.36
Enterprise Value/Revenue
2.82
Enterprise Value/EBITDA
9.16
Financial Highlights
Profitability and Income Statement
Profit Margin
23.30%
Return on Assets (ttm)
11.62%
Return on Equity (ttm)
25.71%
Revenue (ttm)
1.51B
Net Income Avi to Common (ttm)
355.65M
Diluted EPS (ttm)
2.10
Balance Sheet and Cash Flow
Total Cash (mrq)
884.02M
Total Debt/Equity (mrq)
4.90%
Levered Free Cash Flow (ttm)
429.53M